Linear IgA bullous dermatosis is a rare immune-mediated blistering skin disease frequently associated with medication exposure, especially vancomycin, with men and women being equally affected.

[2] Lesions on the skin, mucous membranes, or both may be seen in cases with linear IgA bullous dermatosis (LABD).

[6] Skin lesions typically occur in a wide range of locations, including the hands, feet, genitalia, trunk, and face, especially the perioral area.

Adults experience a lower incidence of developing annular lesions exhibiting peripheral vesiculation compared to children.

[13] There have also been reports of localized variations of LABD that manifest as annular inflammatory plaques or restricted blistering eruptions.

Any mucosal surface, such as those in the mouth, conjunctiva, nose, genitalia, pharynx, larynx, anus, and esophagus, could be impacted.

[24] Many case reports have documented the incidence of LABD in conjunction with solid organ cancers and lymphoproliferative diseases.

[39][40] IgA antibodies directed against various basement membrane antigens, such as type VII collagen (COL7), laminin-332, or laminin gamma 1, are present in certain patients with LABD.

[42] The clinical manifestations of various mucocutaneous disorders may be confused with those of linear IgA bullous dermatosis (LABD).

[10] Linear IgA bullous dermatosis histopathologic features are vague and frequently mimic dermatitis herpetiformis.

[10] First-line treatment for LABD is thought to be dapsone, an immunomodulatory sulfone that has been successfully used to treat a variety of dermatologic illnesses marked by neutrophilic infiltrates.